GlobeStar Therapeutics Corporation
GlobeStar Therapeutics Corporation (GSTC) Revenue
Annual & quarterly revenue history · segment & region breakdown
GSTC · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsGlobeStar Therapeutics Corporation trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from $0.00B in FY2023.
Revenue trend
2023 – 2010 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2023-09-30 | $0.00B | +$0.00B | — |
| 2022-09-30 | $0.00B | +$0.00B | — |
| 2021-09-30 | $0.00B | -$0.00B | -100.00% |
| 2020-09-30 | $0.00B | -$0.00B | -81.88% |
| 2019-09-30 | $0.00B | -$0.00B | -52.25% |
| 2018-09-30 | $0.00B | +$0.00B | — |
| 2017-09-30 | $0.00B | +$0.00B | — |
| 2016-09-30 | $0.00B | -$0.00B | -100.00% |
| 2015-09-30 | $0.00B | -$0.00B | -56.66% |
| 2014-09-30 | $0.00B | +$0.00B | +69.54% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income GlobeStar Therapeutics Corporation receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
GlobeStar Therapeutics Corporation reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from GlobeStar Therapeutics Corporation's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
GSTC revenue · 4 questionsGSTC's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from $0.00B in FY2023.
▸ Source: FMP · GlobeStar Therapeutics Corporation SEC filings · GAAP · GlobeStar Therapeutics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026